$GILD

Assembly Biosciences reports Q1 2026 results with $226.6M cash runway into 2028, completing Phase 1b herpes studies and advancing hepatitis delta candidate toward Phase 2.

Over 25 pharma companies develop 30+ PARP inhibitors in trials, with AstraZeneca and Gilead leading expansion into multiple cancer indications including glioblastoma and prostate cancer.

DelveInsight's 2026 report shows robust rheumatoid arthritis pipeline with 75+ players developing 80+ drugs, featuring novel JAK and BTK inhibitors plus cell-based therapies.

S&P 500 hits record highs with 84% earnings beats and 15.1% growth, as Magnificent Seven tech giants report this week and Fed meets on rates.

Kailera Therapeutics surged 63% on Nasdaq debut as weight-loss drug spinoff from Hengrui Pharma, raising $625M and validating the 'NewCo' model for Chinese pharmaceutical companies.

Kymera Therapeutics receives $45M from Gilead option exercise and FDA Fast Track designation for asthma drug KT-621, with Phase 2b data expected late 2027.

Nurix Therapeutics unveils preclinical data showing protein degradation pipeline effectiveness, with NRX-0305 achieving 142% lifespan extension in melanoma models.

Over 100 pharmaceutical companies compete to develop 120+ NSCLC pipeline drugs, with 30+ in late-stage trials. Precision oncology advances drive innovation in biomarker-selected populations.

Nurix Therapeutics reported Q1 2026 revenue of $6.3M (down 66% YoY) and $87.2M net loss, maintaining $540.7M cash while advancing bexobrutideg clinical program.

Gilead acquires Tubulis for $3.15 billion including milestones, adding HER2-targeting ovarian cancer candidate to oncology pipeline—second major deal in months.

President Trump's executive order imposes 100% tariffs on imported drugs, exempting 13 companies with MFN agreements and U.S. manufacturing commitments through 2029.

Keymed Biosciences receives up to $320M from Gilead's acquisition of its immunotherapy spinoff Ouro Medicines, marking a landmark exit for Chinese biotech.

Waste Management and Gilead Sciences offer attractive dividend-growth opportunities as pullbacks from Middle East tensions create entry points for AI-driven productivity investors.

Galapagos and Gilead form binding collaboration on gamgertamig, an autoimmune T cell engager, with Galapagos receiving 50% of Gilead's $1.675B Ouro Medicines acquisition.

Global bile duct cancer market projected to reach $3.89B by 2030 from $2.59B in 2025, driven by immunotherapy, AI diagnostics, and rising disease prevalence.

SK pharmteco hosts April 8 Cambridge symposium on advanced pharmaceutical manufacturing, featuring leaders from Gilead, Eli Lilly, Amgen, and Antheia discussing continuous production innovations.

Gilead acquires Ouro Medicines for $1.675B upfront, targeting inflammation pipeline expansion. Galapagos NV partners to co-develop lead asset OM336.

Galapagos and Gilead plan to jointly develop an Ouro T cell engager for autoimmune diseases, splitting acquisition costs while Galapagos leads development and Gilead commercializes, freeing $500M in Galapagos cash.

Galapagos and Gilead are in advanced partnership talks for a first-in-class T-cell engager for autoimmune diseases, with 50% cost-sharing and €500 million capital freed for Galapagos.

Cormorant Asset Management exited its $63.63M Arcellx stake in Q4, missing an 80% year-to-date rally capped by Gilead Sciences' $7.8B acquisition announcement.